原发治疗顺序是否影响复发性上皮性卵巢癌的复发后生存?一项真实世界多中心回顾性研究
该多中心回顾性研究纳入2007年9月至2020年6月中国三级医院的853例IIIC-IV期复发性上皮性卵巢癌患者,比较初始肿瘤细胞减灭术(PDS)与新辅助化疗联合间歇性肿瘤细胞减灭术(NACT-IDS)对复发后生存(PRS)的影响。中位PRS为29.3个月(95%CI 27.0-31.5个月)。多因素分析显示NACT-IDS和残留R1/R2病变是PRS的独立危险因素,且NACT-IDS与弥漫性癌病和PFI≤12个月独立相关。
要点
- 在复发性上皮性卵巢癌中,NACT-IDS是复发后生存的独立危险因素(p<0.05)。
- NACT-IDS与弥漫性癌病(IPTW后OR 1.29,95%CI 1.05-1.58)和PFI≤12个月(OR 1.90,95%CI 1.52-2.38)独立相关。
- 原发治疗顺序可能通过改变复发模式和PFI时长影响复发后生存。
核心结论
- 原发治疗顺序可能通过改变复发模式和PFI时长影响复发性上皮性卵巢癌患者的复发后生存。
研究设计与样本
- 真实世界多中心回顾性研究,纳入2007年9月至2020年6月中国三级医院的853例IIIC-IV期复发性上皮性卵巢癌患者,其中NACT-IDS组377例、PDS组476例,采用倾向性评分逆概率治疗加权(IPTW)平衡组间差异。
主要发现
- 总体中位PRS为29.3个月(95%CI 27.0-31.5个月)。
- IPTW调整前后多因素分析均显示NACT-IDS和残留R1/R2病变是PRS的独立危险因素(p<0.05)。
- 弥漫性癌病患者和PFI≤12个月患者的PRS显著更差(p<0.001)。
- 逻辑回归显示NACT-IDS是弥漫性癌病的独立危险因素(OR 1.36,95%CI 1.01-1.82,p=0.040)和PFI≤12个月的独立危险因素(OR 1.59,95%CI 1.08-2.35,p=0.019)。
- IPTW分析中NACT-IDS仍与弥漫性癌病(OR 1.29,95%CI 1.05-1.58,p=0.015)和PFI≤12个月(OR 1.90,95%CI 1.52-2.38,p<0.001)显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the impact of the primary treatment sequence (primary debulking surgery, PDS, versus neoadjuvant chemotherapy and interval debulking surgery, NACT-IDS) on post-relapse survival (PRS) and recurrence characteristics of recurrent epithelial ovarian cancer (REOC). DESIGN: Real-world retrospective study. SETTING: Tertiary hospitals in China. POPULATION: A total of 853 patients with REOC at International Federation of Gynaecology and Obstetrics stages IIIC-IV from September 2007 to June 2020. Overall, 377 and 476 patients received NACT-IDS and PDS, respectively. METHODS: Propensity score-based inverse probability of treatment weighting (IPTW) was performed to balance the between-group differences. MAIN OUTCOME MEASURES: Clinicopathological factors related to PRS. RESULTS: The overall median PRS was 29.3 months (95% CI 27.0-31.5 months). Multivariate analysis before and after IPTW adjustment showed that NACT-IDS and residual R1/R2 disease were independent risk factors for PRS (p < 0.05). Patients with diffuse carcinomatosis and platinum-free interval (PFI) ≤ 12 months had a significantly worse PRS (p < 0.001). Logistic regression analysis revealed that NACT-IDS was an independent risk factor for diffuse carcinomatosis (OR 1.36, 95% CI 1.01-1.82, p = 0.040) and PFI ≤ 12 months (OR 1.59, 95% CI 1.08-2.35, p = 0.019). In IPTW analysis, NACT-IDS was still significantly associated with diffuse carcinomatosis (OR 1.29, 95% CI 1.05-1.58, p = 0.015) and PFI ≤ 12 months (OR 1.90, 95% CI 1.52-2.38, p < 0.001). CONCLUSIONS: The primary treatment sequence may affect the PRS of patients with REOC by altering the recurrence pattern and PFI duration.
引用
- Liu X, Zhao Y, Jiao X, et al. Does the primary treatment sequence affect post-relapse survival in recurrent epithelial ovarian cancer? A real-world multicentre retrospective study. BJOG. 2022. PMID: 36485065. doi:10.1111/1471-0528.17329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。